Author:
de Benedetti Fabrizio,Grom Alexei A.,Brunner Hermine
Abstract
AbstractThe substantial morbidity and mortality associated with refractory systemic JIA underlies the need for new treatment approaches. However, progress in this area has been limited by the difficulty of enrolling these patients in clinical trials with traditional designs, particularly in patients presenting with the life-threatening macrophage activation syndrome. At the NextGen 2022 conference, there was group consensus that using historical cohorts as a control group to avoid the need for a placebo-arm or drug withdrawal was highly desirable and might be acceptable for clinical trials in MAS to support medication efficacy and safety. However, if historic controls were used in a trial, it would be important to ensure that the historic cohort matches the study group in terms of clinical characteristics (such as disease severity and exposure to other medications), and that disease outcome in both groups is assessed using the same outcome measures. The discussions at the NextGen 2022 conference focused on the potential strategies to achieve these goals.
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Garg M, de Jesus AA, Chapelle D, Dancey P, Herzog R, Rivas-Chacon R, Muskardin TLW, Reed A, Reynolds JC, Goldbach-Mansky R, Sanchez GAM. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017;2(16):e94838. https://doi.org/10.1172/jci.insight.94838. PMID: 28814674; PMCID: PMC5621891.
2. FDA. U.S. Food and Drug Administration Kineret. 2020. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl.pdf.
3. FDA. U.S. Food and Drug Administration Ilaris. 2020. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125319s097lbl.pdf.
4. FDA. U.S. Food and Drug Administration Arcalyst. 2021. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125249s049lbl.pdf.
5. De Benedetti F, Grom AA, Brogan P, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert G, Quartier P, Antón J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C. Emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2022;(in press).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献